Considerations in treatment choice for metastatic breast cancer

Breast Cancer

Volumn 15, Issue 1, 2008, Pages 35-39

  Jones, Stephen E ^a,b  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b TEXAS ONCOLOGY   (United States)

Author keywords

Adjuvant therapy; Cytotoxic therapy; Metastatic breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST TUMOR; FEMALE; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS;

EID: 43149105789     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-007-0005-0     Document Type: Conference Paper

References (24)

1. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005;10 Suppl 3:20-9.
2. Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Kostler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2007;18:215-25. (Pubitemid 46323085)
3. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Word WC. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003;21:588-92. (Pubitemid 46621890)
4. Albain KS, Nag S, Calderillo-Ruiz J, Jordaan J, Llombart A, Pluzanska A, Pawlicki M, Melemed AS, O'Shaughnessy J, Reyes JM. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol 2004;22 Suppl 14: Abstract 510.
5. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, van Hanzel G, Verma S, Leonard R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812-23. (Pubitemid 34651510)
6. Soto C, Torrecillas L, Reyes S, Ramirez M, Perez L, Cervantes G, Gonzalez F, Tellez E, Cortes P, Benitez H. Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): sequential vs. combined therapy results from a MOSG randomised phase III trial. J Clin Oncol 2006;24 Suppl 18: Abstract 570.
7. National Comprehensive Cancer Network: NCCN clinical practice guidelines in OncologyTM: breast cancer. 2007. http://www.nccn.org.
8. Kataja V, Colleoni M, Bergh J. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC). Ann Oncol 2005;16 Suppl 1:i10-i12. (Pubitemid 40872970)
9. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339:900-5. (Pubitemid 28446849)
10. Chan S, Friedrichs K, Noel D, Pinter T, van Belle S, Vorobiof D, Duarte R, Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez-Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol. 1999;17:2341-54. (Pubitemid 29368232)
11. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005;23:5542-51.
12. Valero V, Jones SE, von Hoff D, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza- Guerra LT, Earhart RH, Hortobágyi GN, Burris HA III. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998;16:3362-8. (Pubitemid 28481633)
13. Yonemori K, Katsumata N, Uno H, Matsumoto K, Kouno T, Tokunaga S, Yamanaka Y, Shimizu C, Ando M, Takeuchi M, Fujiwara Y. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. Breast Cancer Res Treat. 2005;89:237-41. (Pubitemid 43293070)
14. Sawaki M, Ito Y, Hashimoto D, Mizunuma N, Takahashi S, Horikoshi N, Tada K, Kasumi F, Akiyama F, Sakamoto G, Imai T, Nakao A, Hatake K. Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study. Tumori. 2004;90:36-9. (Pubitemid 38541724)
15. Nishimura R, Ogawa T, Kato M, Tanaka M, Hamada Y, Shibata T, Ishikawa E, Koga T, Mitsuyama S, Tamura K. Weekly paclitaxel in the treatment of advanced or metastatic breast cancer previously treated or not treated with docetaxel: a phase II study. Chemotherapy. 2005;51:126-31. (Pubitemid 40981070)
16. Ma CX, Steen P, Rowland KM, Niedringhaus RD, Fitch TR, Kugler JW, Hillman DW, Perez EA, Ingle JN, Adjei AA. A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. Ann Oncol. 2006;17:226-31. (Pubitemid 43160110)
17. Airoldi M, Cattel L, Passera R, Pedani F, Delprino L, Micari C. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. Am J Clin Oncol. 2006;29:490-4. (Pubitemid 44536032)
18. Alexopoulos A, Karamouzis MV, Ioannides H, Stavrinides H, Ardavanis A, Stavrakakis J, Georganta C, Kandilis K, Rigatos G. Salvage treatment with biweekly administration of paclitaxel (P) and gemcitabine (G) in patients (pts) with metastatic breast cancer (MBC) heavily pretreated with anthracycline and docetaxel containing regimens. J Clin Oncol 2005;23 Suppl 16: Abstract 836.
19. Loesch DM, Asmar L, McIntyre KJ, Doanne LL, McKittrick RJ, Montillo M, Vukelja SJ, Zhan F, Boehm KA, O'Shaughnessy J. Phase II trial of gemcitabine plus carboplatin (plus trastuzumab in HER2+ patients) in metastatic breast cancer patients. In: 28th San Antonio Breast Cancer Symposium; Abstract 6092. 2005.
20. Blum JL, Dees EC, Vukelja SJ, Amare M, Gill DP, McMahon RT, Ilegbodu D, Asmar L, O'Shaughnessy JA. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy. Clin Breast Cancer. 2007;7:465-70. (Pubitemid 46424283)
21. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-92. (Pubitemid 32222155)
22. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265-74. (Pubitemid 46207001)
23. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66:1630-9. (Pubitemid 43259947)
24. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-43. (Pubitemid 46021510)